EX9 Stock Chart & Stats
CHF53.45
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF53.21 - CHF59.24
Previous CloseN/A
VolumeN/A
Average Volume (3M)85.00
Market Cap
CHF13.95B
Enterprise ValueCHF14.20B
Total Cash (Recent Filing)CHF892.02M
Total Debt (Recent Filing)CHF162.20M
Price to Earnings (P/E)20.1
Beta0.72
Next Earnings
Feb 09, 2027EPS Estimate
0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.45
Shares Outstanding247,781,700
10 Day Avg. Volume85
30 Day Avg. Volume85
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)5.48
Price to Sales (P/S)5.10
P/FCF Ratio14.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF47.26Price Target Upside― Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)2.94
Revenue Forecast (FY)CHF2.10B
Bulls Say, Bears Say
Bulls Say
CABOMETYX Franchise Leadership And GrowthThe core cabozantinib franchise is expanding through both revenue growth and market-share gains across important oncology indications. Leading prescribing positions and rising prescription volume support durable commercial strength, while the established franchise provides a foundation for funding future pipeline development.
Strong Cash Generation And LiquidityRobust operating and free cash flow, combined with substantial cash and marketable securities, gives Exelixis meaningful financial flexibility. Low leverage further reduces balance-sheet risk and supports continued investment in clinical programs, business development, and shareholder returns without relying heavily on new debt.
Protected Commercial Exclusivity And Pipeline ExpansionThe patent ruling extends protection around a key commercial product and helps preserve the economic value of the existing franchise. At the same time, the broad zanzalintinib development program and new candidates create opportunities to diversify growth beyond the current lead medicine over time.
Bears Say
Gross-to-net And Margin PressureHigher gross-to-net deductions reduce the revenue retained from reported product sales and can pressure the economics of the commercial franchise. The sharp decline in TTM gross margin also indicates recent cost or mix pressure, which could limit how much revenue growth converts into durable earnings and cash flow.
Delayed Zanzalintinib Regulatory TimelineThe extended FDA review delays a potential zanzalintinib launch in metastatic colorectal cancer and postpones a possible second growth franchise. The delay also reflects the significance of updated safety and efficacy data, keeping regulatory timing and approval execution as material uncertainties for pipeline-driven expansion.
Dependence On The Cabozantinib FranchiseReliance on one main commercial franchise concentrates Exelixis's revenue base around the continued performance of CABOMETYX and its approved indications. This makes future growth more dependent on sustained prescribing, market access, and successful pipeline launches that can broaden the company's product mix.
Exelixis News
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was CHF53.21 and its highest was CHF59.24 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is CHF13.95B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Feb 09, 2027 which is in 100 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Oct 29, 2026. The company reported CHF0.774 earnings per share for the quarter, beating the consensus estimate of CHF0.731 by CHF0.044.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.79.
How many shares outstanding does Exelixis have?
Exelixis has 247,781,700 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of CHF0.774 in its last earnings report, beating expectations of CHF0.731. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in CH:EX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF47.26 (― Upside)
CHF47.26 (― Upside)
Blogger Sentiment
Bullish
CH:EX9 Sentiment 63%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.19%
12-Months-Change
Fundamentals
Return on Equity
45.54%
Trailing 12-Months
Asset Growth
-10.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EX9 Company Deck
EX9 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Management reported solid revenue and CABOMETYX growth, improving market share in RCC and NET, robust zanzalintinib enrollment and broad pipeline expansion, while also highlighting a substantial potential CRC opportunity and continued share repurchases. The main challenges were sequentially higher operating expenses and taxes, a higher full-year gross-to-net estimate, volatile clinical-trial sales, and the previously reduced revenue guidance.View all CH:EX9 earnings summariesEX9 Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
